Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Initiation of biphasic insulin aspart 30/70 in subjects with type 2 diabetes mellitus in a largely primary care-based setting in Sweden.

Berntorp, Kerstin LU ; Haglund, Mattias LU ; Sjövall Larsen, Sara ; Petruckevitch, Ann and Landin-Olsson, Mona LU (2011) In Primary Care Diabetes 5(2). p.89-94
Abstract

AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, biphasic insulin aspart 30 (BIAsp 30) in the treatment of type 2 diabetes mellitus (T2DM), there is limited documentation of its use in primary care-based clinical practice.

METHODS: An observational study investigating the safety and efficacy of BIAsp 30 in routine clinical practice was conducted. Patients were followed up 3 and 6 months after initiating insulin treatment. Safety and efficacy measures were documented.

RESULTS: During the course of the study, 1154 patients were included (age range 20-95 years), of whom 89% completed the 6-month follow-up period. Mean HbA(1c) at baseline was 8.8% (73mmol/mol), and had improved to... (More)

AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, biphasic insulin aspart 30 (BIAsp 30) in the treatment of type 2 diabetes mellitus (T2DM), there is limited documentation of its use in primary care-based clinical practice.

METHODS: An observational study investigating the safety and efficacy of BIAsp 30 in routine clinical practice was conducted. Patients were followed up 3 and 6 months after initiating insulin treatment. Safety and efficacy measures were documented.

RESULTS: During the course of the study, 1154 patients were included (age range 20-95 years), of whom 89% completed the 6-month follow-up period. Mean HbA(1c) at baseline was 8.8% (73mmol/mol), and had improved to 7.2% (55mmol/mol) after 6 months of treatment. The rate of total hypoglycaemia at completion of the study was 4.1 events per patient year. Major hypoglycaemic events were rare (two in total).

CONCLUSIONS: BIAsp 30 was initiated safely and effectively in insulin-naïve patients with T2DM. The safety and efficacy profile observed in clinical trials was confirmed in this largely primary care-based setting in Sweden.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adult, Aged, Aged, 80 and over, Biomarkers/blood, Biphasic Insulins, Blood Glucose/drug effects, Body Weight/drug effects, Diabetes Mellitus, Type 2/blood, Female, Glycated Hemoglobin/metabolism, Health Services Research, Humans, Hypoglycemia/chemically induced, Hypoglycemic Agents/adverse effects, Insulin/adverse effects, Insulin Aspart, Insulin, Isophane, Male, Middle Aged, Primary Health Care, Prospective Studies, Sweden/epidemiology, Time Factors, Treatment Outcome, Young Adult
in
Primary Care Diabetes
volume
5
issue
2
pages
6 pages
publisher
Elsevier
external identifiers
  • wos:000304279500004
  • pmid:21440523
  • scopus:79958858255
  • pmid:21440523
ISSN
1878-0210
DOI
10.1016/j.pcd.2011.02.003
language
English
LU publication?
yes
id
38dbfdd3-cace-4b15-b000-55bfe380ed14 (old id 1883404)
date added to LUP
2016-04-04 07:27:16
date last changed
2025-04-04 14:15:00
@article{38dbfdd3-cace-4b15-b000-55bfe380ed14,
  abstract     = {{<p>AIMS: Despite a wealth of clinical trial data supporting use of the premixed insulin analogue, biphasic insulin aspart 30 (BIAsp 30) in the treatment of type 2 diabetes mellitus (T2DM), there is limited documentation of its use in primary care-based clinical practice.</p><p>METHODS: An observational study investigating the safety and efficacy of BIAsp 30 in routine clinical practice was conducted. Patients were followed up 3 and 6 months after initiating insulin treatment. Safety and efficacy measures were documented.</p><p>RESULTS: During the course of the study, 1154 patients were included (age range 20-95 years), of whom 89% completed the 6-month follow-up period. Mean HbA(1c) at baseline was 8.8% (73mmol/mol), and had improved to 7.2% (55mmol/mol) after 6 months of treatment. The rate of total hypoglycaemia at completion of the study was 4.1 events per patient year. Major hypoglycaemic events were rare (two in total).</p><p>CONCLUSIONS: BIAsp 30 was initiated safely and effectively in insulin-naïve patients with T2DM. The safety and efficacy profile observed in clinical trials was confirmed in this largely primary care-based setting in Sweden.</p>}},
  author       = {{Berntorp, Kerstin and Haglund, Mattias and Sjövall Larsen, Sara and Petruckevitch, Ann and Landin-Olsson, Mona}},
  issn         = {{1878-0210}},
  keywords     = {{Adult; Aged; Aged, 80 and over; Biomarkers/blood; Biphasic Insulins; Blood Glucose/drug effects; Body Weight/drug effects; Diabetes Mellitus, Type 2/blood; Female; Glycated Hemoglobin/metabolism; Health Services Research; Humans; Hypoglycemia/chemically induced; Hypoglycemic Agents/adverse effects; Insulin/adverse effects; Insulin Aspart; Insulin, Isophane; Male; Middle Aged; Primary Health Care; Prospective Studies; Sweden/epidemiology; Time Factors; Treatment Outcome; Young Adult}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{89--94}},
  publisher    = {{Elsevier}},
  series       = {{Primary Care Diabetes}},
  title        = {{Initiation of biphasic insulin aspart 30/70 in subjects with type 2 diabetes mellitus in a largely primary care-based setting in Sweden.}},
  url          = {{http://dx.doi.org/10.1016/j.pcd.2011.02.003}},
  doi          = {{10.1016/j.pcd.2011.02.003}},
  volume       = {{5}},
  year         = {{2011}},
}